We are now focused on raising capital to develop marketable products and services:
- Two catabodies to treating amyloid diseases of the heart, musculoskeletal system and brain (catabodies to transthyretin, amyloid β and tau) and a lead E-vaccine for prophylaxis and therapy of HIV infection.
- Expanding the medical reach of the technology platform by on-demand production of catabodies and E-vaccines to any pre-specified target protein.
Business Development Consultant
|Robert P. Friedland, M.D.||Professor,
University of Louisville, Louisville, KY
|Joel Buxbaum, M.D.||Professor,
Scripps Research Institute, La Jolla, CA
|Miguel A. Escobar, M.D.||Professor,
University of Texas Health Science Center, Houston, TX
|Carl Hanson, Ph.D.||CLIA Lab Director
California Department of Public Health, Richmond, CA
|Seth Pincus, Ph.D.||Professor,
Montana State University, Bozeman, MT